Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428113 | 1.00 | PPARA (0.61) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL2009896 | 1.00 | PPARA (0.61) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL13702217 | 0.95 | PPARA (0.56) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL13702216 | 0.95 | PPARA (0.56) | PPARAPPARGACEPPARDKLK7 | |
| Dioxane SCHEMBL27814606 | 0.93 | PPARA (0.54) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL8177426 | 0.93 | PPARA (0.58) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL8178286 | 0.93 | PPARA (0.58) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL1517760 | 0.93 | PPARA (0.55) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL13007476 | 0.93 | PPARA (0.55) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL2011835 | 0.93 | PPARA (0.55) | PPARAPPARGACEKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | claimed |
| EP-4695257-A1 | PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF | Harman Finochem Limited (IN) | 2026-02-18 | — | — | EP | claimed |
| WO-2024214109-A1 | PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF | HARMAN FINOCHEM LIMITED (IN) | 2024-10-17 | — | — | WO | claimed |
| CN-111825742-B | Polypeptide solid phase synthesis of CTPA as special coupling agent for amino acid ionic liquid | 陈铭 | 2024-01-30 | — | — | CN | claimed |
| WO-2023148764-A1 | NOVEL CHOLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES AND USES THEREOF | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2023-08-10 | — | — | WO | claimed |
| CN-115490684-A | 3S-1,2,3, 4-tetrahydro-beta-carboline-3-methyl-amino acid, preparation thereof, antithrombotic activity and application thereof | 首都医科大学 | 2022-12-20 | — | — | CN | claimed |
| CN-115477648-A | Carboline derivative, preparation method thereof and application thereof in preparing antitumor drugs | 首都医科大学 | 2022-12-16 | — | — | CN | claimed |
| CN-109721522-A | A kind of high-quality N- tertbutyloxycarbonyl-L-Glutimic acid benzyl ester industrialized preparing process | 常州吉恩药业有限公司 | 2019-05-07 | — | — | CN | claimed |
| CN-102796171-B | Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | claimed |
| CN-102796171-A | Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | claimed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | disclosed |
| EP-4695257-A1 | PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF | Harman Finochem Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| EP-0482605-A2 | HTLV-II derived peptide | Kuraray Co., Ltd. (JP) | 1992-04-29 | — | — | EP | disclosed |
| CN-1059725-A | Novel methotrexate derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1992-03-25 | — | — | CN | disclosed |
| EP-0474273-A2 | A polypeptide capable of interacting with thrombin | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4629736-A | HIGH FIBRINOLYTIC ACTION; WATER SOLUBILITY; ANTICOAGULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-16 | — | — | US | disclosed |
| EP-0136879-A2 | Fatty acid derivatives and processes of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | PPARA 776/4885PPARG 1348/4885ACE 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.